Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage
biopharmaceutical company developing toll-like receptor and RNA
therapeutics for patients with cancer and rare diseases, today is
reporting new pre-clinical data from its ongoing intratumoral
IMO-2125 development program at the Third Annual CRI-CIMT-EATI-AACR
International Cancer Immunotherapy Conference being held in
Frankfurt, Germany.
In the poster presentation entitled, “Intratumoral IMO-2125
Treatment in Combination with Anti-CTLA4 mAB Induces Durable
Anti-Tumor Reponses Associated with Tumor-Specific Memory in
Preclinical Studies,” presented by Daqing Wang, Ph.D., Principal
Scientist & Group Leader, Idera Pharmaceuticals, demonstrated
that intratumoral injections of IMO-2125 enhance anti-tumor
responses in combination with CTLA4 blockade. Further this
study demonstrated the combination of IMO-2125 and anti-CTLA4
achieves prolonged, durable anti-tumor effect.
In this study, mice whose tumors completely regressed survived
more than one year after the combination treatment was
administered. These animals maintained anti-tumor responses
upon tumor re-challenge indicative of memory T-cell induction by
the combination of IMO-2125 and anti-CTLA4. Additionally,
IMO-2125 delivered intratumorally has been shown to mediate tumor
microenvironment changes including infiltration of T-cells and
immune checkpoint gene up-regulation.
“These findings further support our current clinical trials
which are designed to demonstrate that the combination of
intratumoral IMO-2125 and Ipilimumab provides an opportunity to
break the resistance to anti-PD-1 therapy and lead to durable
effect in this patient population, one that clearly represents a
significant unmet need in immuno-oncology,” stated Joanna Horobin,
C.B., Ch.B., Idera’s Chief Medical Officer. “We look forward
to presenting further data from our ongoing clinical trial this
weekend at ESMO as well as additional translational data from our
trials at a future medical conference later this year.”
A copy of the poster presentation is currently available on
Idera’s corporate website at
http://www.iderapharma.com/our-approach/key-publications/.
Investor Event and WebcastIdera will host a
conference call and live webcast on Monday, September 11 at 9:00
A.M. EDT to review the data being presented here as well as at ESMO
along with discussion of next steps for the IMO-2125 development
program. To participate in the conference call, please dial
(844) 882-7837 (domestic) and (574) 990-9824 (international).
The webcast can be accessed live or in archived form in the
“Investor’s” section of the company’s website at
www.iderapharma.com. The company plans to post a slide
presentation on Monday, September 11, 2017 to the Idera corporate
website in the “Investors” section which will be referenced during
the conference call.
About IMO-2125 IMO-2125 is a toll-like
receptor (TLR) 9 agonist that received orphan drug designation from
the FDA in 2017 for the treatment of melanoma Stages IIb to IV. It
signals the immune system to create and activate cancer-fighting
cells (T-cells) to target solid tumors in refractory melanoma
patients. Currently approved immuno-oncology treatments for
patients with metastatic melanoma, specifically check-point
inhibitors, work for some but not all, as many patients’ immune
response is missing or weak and thus they do not benefit from the
checkpoint therapy making them so-called “refractory”. The
combination of ipilimumab and IMO-2125 appears to activate an
immune response in these patients who have exhausted all options.
Intratumoral injections with IMO-2125 is designed to selectively
enable the T-cells to recognize and attack cancers that remained
elusive and unrecognized by the immune system exposed to checkpoint
inhibitors alone, while limiting toxicity or impact on healthy
cells in the body.
About Metastatic MelanomaMelanoma is a type of
skin cancer that begins in a type of skin cell called melanocytes.
As is the case in many forms of cancer, melanoma becomes more
difficult to treat once the disease has spread beyond the skin to
other parts of the body such as by through the lymphatic system
(metastatic disease). Because melanoma occurs in younger
individuals, the years of life lost to melanoma are also
disproportionately high when compared with other cancers.
Although melanoma is a rare form of skin cancer, it comprises over
75% of skin cancer deaths. The American Cancer Society
estimates that there were approximately 76,000 new invasive
melanoma cases and 10,000 deaths from the disease in the USA in
2016. Additionally, according to the World Health
Organization, about 132,000 new cases of melanoma are diagnosed
around the world every year.
About Idera PharmaceuticalsHarnessing the
approach of the earliest researchers in immunotherapy and the
company’s vast experience in developing proprietary immunology
platforms, Idera’s lead development program is focused on priming
the immune system to play a more powerful role in fighting cancer,
ultimately increasing the number of people who can benefit from
immunotherapy. Idera continues to invest in research and
development, and is committed to working with investigators and
partners who share the common goal of addressing the unmet needs of
patients suffering from rare, life-threatening diseases. To learn
more about Idera, visit www.iderapharma.com.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. All statements,
other than statements of historical fact, included or incorporated
in this press release, including statements regarding the Company's
strategy, future operations, collaborations, intellectual property,
cash resources, financial position, future revenues, projected
costs, prospects, plans, and objectives of management, are
forward-looking statements. The words "believes," "anticipates,"
"estimates," "plans," "expects," "intends," "may," "could,"
"should," "potential," "likely," "projects," "continue," "will,"
and "would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Idera cannot guarantee
that it will actually achieve the plans, intentions or expectations
disclosed in its forward-looking statements and you should not
place undue reliance on the Company's forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated or implied
by its forward-looking statements. Factors that may cause such a
difference include: whether interim results from a clinical trial,
such as preliminary results reported in this release, will be
predictive of the final results of the trial, whether results
obtained in preclinical studies and clinical trials will be
indicative of the results that will be generated in future clinical
trials, including in clinical trials in different disease
indications; whether products based on Idera's IMO-2125 will
successfully advance through the clinical trial process on a timely
basis or at all and receive approval from the United States Food
and Drug Administration or equivalent foreign regulatory agencies;
whether, if the Company's products receive approval, they will be
successfully distributed and marketed; and such other important
factors as are set forth under the caption "Risk Factors" in the
Company's Annual Report on form 10K for the period ended December
31, 2016 and in the Company’s quarterly report on form 10-Q for the
period ended June 30, 2017. Although Idera may elect to do so at
some point in the future, the Company does not assume any
obligation to update any forward-looking statements and it
disclaims any intention or obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Investor and Media Contact
Robert Doody
Vice President, Investor Relations and Corporate Communications
Office: 617-679-5515
Mobile: 484‐639‐7235
rdoody@iderapharma.com
Theresa Dolge
Chief Media Relations Officer
Tonic Life Communications
Office: 215-928-2748
Theresa.dolge@toniclc.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024